Gain Therapeutics Inc. (GANX): Market Cap to Revenue Ratio

Symbol and logo of brand Gain Therapeutics Inc. (GANX)

Gain Therapeutics, Inc. (GANX) develops treatments for neurodegeneration by utilizing supercomputer analysis to identify enzyme regulators. High patent barriers and stringent FDA oversight protect the company's developments. The startup is currently focusing on clinical trials for a Parkinson's disease drug. This price-to-sales chart reflects the business valuation trend, with the current ratio standing at 653.80.

GANX: Gain Therapeutics Inc. Market Cap to Revenue 07/04/2022 - 05/14/2024

Analytical breakdowns for gaintherapeutics.com (GANX)

Fundamental company analysis:Gain Therapeutics, Inc., GANX
Finished products of Gain Therapeutics, Inc.

Complex bio-logistics and cold chain supply management drive the operational costs of Gain Therapeutics, Inc. By analyzing the company's normalized P/S ratio, an investor assesses market capitalization relative to generated revenue. This ratio is calculated by dividing the total business value by annual revenue, measuring the premium for future growth. The trend of this indicator helps determine the extent of the asset's overvaluation or the potential for a fundamental correction.

Competing companies

HCA (HCA Healthcare) - Market Capitalization-to-Revenue Ratio|Tenet Healthcare Corporation - Market Cap to Revenue|Fresenius Medical (FMS) - Price to Sales|Solventum Corp - P/S Multiple|Price-to-Sales Ratio EHC|Universal Health Services (UHS) - Price-to-Revenue Ratio|DaVita - Market Capitalization-to-Revenue Ratio|Market Cap to Revenue RDNT|OPCH: Market Capitalization-to-Revenue Ratio|Market Cap to Revenue SGRY (Surgery Partners, Inc.)|PINC (Premier, Inc.) - Market Capitalization-to-Revenue Ratio|National Vision - Market Cap to Revenue|Price-to-Revenue Coefficient Progyny Inc (PGNY)|Ardent Health - P/S Multiple|Price-to-Revenue Coefficient Select Medical Corp SEM|ASTH: P/S Multiple|Market Cap to Revenue Ratio MD|USPH (US Physical Therapy Inc) - P/S Multiple|PNTG: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Organogenesis Corp (ORGO)|NUTX (Nutex Health Corp) - Market Capitalization-to-Revenue Ratio|P/S Multiple AUNA (Auna S.A.)|SBC Medical Group Holdings Inc (SBC) - Price to Sales|EOLS - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio CYH (Community Health Systems Inc)|SKIN (beautyhealth.com) - Market Cap to Revenue|Market Cap to Revenue Ratio MDWD|Price-to-Revenue Ratio biote Corp.|Price to Sales thejoint.com JYNT|P/S Multiple DCGO|Market Cap to Revenue P3 Health PIII|P/S Multiple EUDA (EUDA Health Holdings)|BMGL (Basel Medical Group Limited) - Price-to-Sales Ratio|CLGN - Price-to-Revenue Ratio|Price to Sales cuprina.com.sg|CCM: P/S Multiple|AMS: Market Cap to Sales Volume|MRM (MEDIROM Corp) - P/S Multiple|ALBT: Market Capitalization-to-Revenue Ratio|P/S Multiple DHAI|Longevity Health Holdings - Market Cap to Revenue Ratio|Price-to-Revenue Ratio NewGenIvf Group Ltd NIVF|ATIP (atipt.com) - Price-to-Sales Ratio|CMAX: Market Cap to Revenue|Price to Sales Kindly Health|ModivCare (MODV) - Price-to-Revenue Ratio|NVOS (novointegrated.com) - Price-to-Revenue Ratio|SSY (SunLink Health Systems Inc.) - P/S Multiple|BACK (IMAC Holdings Inc) - Market Cap to Sales Volume